Psoriasis

Several systemic therapies are available for the treatment of patients with moderate to severe psoriasis. Continued research has further elucidated the immunopathogenesis of the disease, leading to the development of novel biologic agents that are proving to more effectively and safely address moderate to severe psoriatic lesions.

New AAD-NPF guidelines focus on biologics, topical therapy, systemic non-biological therapies, management of pediatric patients, use of phototherapy and comorbidities.

According to a study conducted by Galderma, both rosacea and psoriasis have a significant QOL impact on patients, with a proportion of patients reporting feelings of anxiety and depression due to their disease.